ケンタッキー州における多発性骨髄腫の臨床試験
ケンタッキー州内の拠点で、多発性骨髄腫に関する15件の研究が参加者を募集しています。
ケンタッキー州内の都市
公式研究テキスト（英語）
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Louisville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07518186A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT04634552A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Norton Cancer Institute, Louisville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05552222Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Norton Healthcare, Inc., Louisville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT04879043Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Norton Women's and Children's Hospital, Louisville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06297226Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Joseph Radiation Oncology Resource Center, Lexington
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Louisville
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/14更新 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Norton Cancer Institute St. Matthews, Louisville
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT07280013Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Flaget Memorial Hospital, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Joseph Hospital, Lexington
- 他4件
被験者募集中第3相
全年齢 · 全性別 · 2026/06/10更新 · NCT05561387A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- Norton Cancer Institute, Louisville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/13更新 · NCT05828511Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/20更新 · NCT03761108cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Corbin, Corbin
- Baptist Hardin, Elizabethtown
- Baptist Lexington, Lexington
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- University of Kentucky/ Markey Cancer Center, Lexington
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/25更新 · NCT05722418ClinicalTrials.govより、2026/10/04時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。